KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data

Key Takeaways KYTX surged 23% after its registrational phase II KYSA-8 study met the primary endpoint in SPS.Kyverna Therapeutics reported a 46% median T25FW improvement, with 81% of patients exceeding a 20% gain.KYTX showed broad functional gains, 67% shed walking aids by Week 16 with a manageable safety profile.Shares of Kyverna Therapeutics (KYTX) surged 23.2% on Monday after the company reported positive top-line data from a registrational mid-stage study of its investigational candidate, mivocabtagene ...